SUMMARY The use of tumour associated antigens in the diagnosis of serous effusions was studied in 76 patients with benign and 200 patients with malignant disease. Tissue polypeptide antigen (TPA), a fetoprotein, and CA 125 were found to be of little value. At cut off points of 3 ng/ml, 10 U/ml, and 30 U/ml, respectively, carcinoembryonic antigen (CEA), biliary glycoprotein I (BGP I), and CA 19-9 discriminated between benign and malignant serous effusions with a sensitivity of between 24% and 67%. The 
We describe an investigation into the use of tumour markers for the discrimination of benign and malignant serous effusions. Although conventional cytology, the classic diagnostic tool for ascitic and pleural effusions, detects malignant cells with a specificity of almost 100%, its sensitivity is unsatisfactory. Various investigators have reported that routine cytological examinations recognise malignant cells in serous effusions with a sensitivity of between only 28 and 60%.'" In our series positive cytological results were noted in only 42 of 139 (30%) serous effusions from patients with histologically confirmed malignancies.
Tumour associated antigens may be used in the diagnosis of serous effusions in two ways: firstly, the antigen titres may be determined in the effusion fluid by methods used for the examination of serum; secondly, the antigens may be detected immunocytochemically in cells from the effusion.
For carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA), biliary glycoprotein I (BGP I), and CA and CA 125, we tested the ability of both methods to discriminate between benign and malignant causes of serous effusions and, in addition, the value ofdetermining concentrations of aL fetoprotein (AFP) in serous effusion fluid. Serum concentrations of CEA and CA 125 were also determined in some of the patients.
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Patients and samples One hundred and seventy six pleural effusions, 97 ascitic effusions, and three abdominal drainage fluid specimens were collected from 276 patients aged between 18 and 83 years. Two hundred samples came from patients who had been documented as having malignant disease on the basis of clinical evaluation together with radiological studies, surgical biopsy, or necropsy. In all but eight cases the origin of the neoplasm was clearly established. In 76 patients none of the examinations showed evidence of malignant disease. The diagnoses of all patients are listed in table 1 . Necropsy was performed in 32 patients between one week and one year after collection of serous effusion fluid samples. In all but two malignant cases (n = 24) tumour was found in the pleura or peritoneum.
CONVENTIONAL CYTOLOGY
Conventional cytological diagnoses were made by three independent observers without knowledge of the clinical diagnoses from cytospin preparations stained by the Pappenheim technique and periodic acid Schiff reagent. The findings were recorded as "positive", "negative", or "suspicious" for the presence of malignant cells.
IMMUNOCYTOCHEMICAL STAINING ANTIBODIES
Indirect immunocytochemical staining using peroxidase or alkaline phosphatase conjugated antibodies 19-9 and Mezger, Permanetter, Gerbes, Wilmanns, Lamerz CA 125 by commercial immunoradiometric assays (Mallinckrodt Diagnostica, Dietzenbach, West Germany) according to the manufacturer's instructions. CEA and CA 125 concentrations were also determined in samples collected within three days after or before the puncture of the effusion in some of the patients.
The Mann-Whitney U test was used to assess the significance of differences in tumour marker values among patients with benign and malignant diseases.
The X2 test was used to assess the correlation oftumour marker concentrations in serous effusion fluid and positive immunocytochemical findings. For comparison of serous effusion fluid and serum tumour marker values, the linear regression and the rank correlation coefficient (rj) were determined. Optimal cut off limits for the discrimination of benign and malignant serous effusions were set with the use of receiver operating characteristic (ROC) diagrams. All statistical tests were performed as described by Sachs (fig 1) . Rabbit anti-CEA was used for most examinations as it gave the most intense staining.
In almost all specimens a diffuse or droplet-like (fig 2) . A droplet-like staining of the cytoplasm of mesothelia was also observed in some cases. Effusions containing mesothelial or carcinoma cells positive for BGP I were found in patients with breast and gastrointestinal carcinomas and non-small cell lung cancer. In two cases of ovarian carcinoma, tumour cells were weakly stained.
In 11 of 14 serous effusions of ovarian carcinoma, tumour cells were labelled by OC 125. Positive cells, however, were also found in benign effusions and could be defined by their morphology as small clusters of proliferating mesothelia (fig 3) , and occasionally as .. P20! 638 pleuritis, sepsis, cirrhosis, congestive heart failure (3-6 to 9 ng/ml) and rupture ofthe oesophagus (390 ng/ml). BGP I was raised in bronchial adenoma (52 
Discussion
In only about a third of the malignant serous effusions of our series were tumour cells detected by cytology alone, and this agrees with the findings of previous publications. There are three possible causes of the unsatisfactory sensitivity of conventional cytology. The effusion might be caused by a concomitant benign disease. In our series, however, in almost all malignant cases tumour was present in the pleura or the peritoneum at necropsy. Furthermore, in spite of disease in the serous membranes none or only a few tumour cells may have been released into the effusion fluid. The difficulty in identifying tumour cells arises from the polymorphism of proliferating mesothelial cells in benign as well as in malignant disorders of the pleura or the peritoneum. These proliferating mesothelial cells must not be confused with tumour cells, and a positive diagnosis must be made with caution.
Numerous simple laboratory tests have been assessed for their capacity to differentiate benign from malignant effusions, such as the content of lactic acid dehydrogenase,'2 '5 glucose concentration,'2"8 protein concentration,'2 13 '9 lactic acid content,'4 162' cell count,'6 17 pH values,'6 albumin,22 and red cell count.23 For some of these tests, the first optimistic reports were not confirmed in other studies. Other tests were applicable only in sterile effusions and gave false positive results in infected patients. The most promising examinations of this type are the determination of cholesterol24 and fibronectin,2526 although both tests seem to be useful mainly in ascitic fluid and less so in pleural effusions.
Although until now none of the so-called tumour associated antigens could be shown to be specific for malignant disease, their determination seems to be a more direct approach to establishing the nature of the underlying disease. Numerous reports have documented the usefulness of determining CEA in serous effusion fluid as well as its immunocytochemical demonstration.
In our study the staining of granulocytes by antibodies to CEA and BGP I seems to have been caused by a cross reaction with non-specific cross reacting antigen (NCA).2728 It did not impair the value of these antibodies as granulocytes could easily be recognised by their morphology and could not be confused with tumour cells. Our data confirm that a positive reaction for CEA excludes a malignant mesothelioma or a non-neoplastic proliferation of serosa cells.2"33 The diversity of the immunocytochemical staining for CEA in different tumour types is consistent with serological and immunohistochemical studies about the distribution of this antigen.9 1116 TPA occurs closely related to the intermediate filaments of epithelial and carcinoma cells.3738 As in mesothelia the cytoskeleton proteins of epithelial and mesenchymal cells can be shown,39 and it is not surprising that we also found TPA in mesothelia.
OC 125 recognises a determinant (CA 125) which is associated with epithelial ovarian neoplasms. 
found mostly in gastrointestinal and ovarian carcinomas and only in a few breast carcinomas and non-small cell lung cancer.
The misdiagnosis of a neoplasm in patients with a benign disease could lead to very far reaching sequelae. Normally occurring antigens in serous membranes or in benign diseases are therefore not suitable for diagnostic tests. TPA and CA 125, therefore, do not seem to be suitable for the immunocytochemical diagnosis of tumours in serous effusions. CA 148 and epithelial membrane antigen549 have been described as occurring only in malignant effusions. Other investigators, however, detected the antigens in mesothelia in benign specimens as well.3033 Antisera to keratin,33 a fetoprotein,32 pregnancy specific ,B 1-glycoprotein32 and placental alkaline phosphatase32 were found to stain only carcinoma cells, but provided little additional information when compared with CEA. The distribution ofdifferent molecular weight keratins showed that mesothelial and adenocarcinoma cells had a different staining pattern.5' The monoclonal antibody B 72-3 was developed by immunising mice with a membrane enriched fraction of a human carcinoma. Ninetyfive per cent staining of adenocarcinoma cells in serous effusions and the absence of mesothelial cell staining has recently been reported for this antibody.52 To our knowledge, the remarkable sensitivity of this monoclonal antibody has so far not been confirmed by other investigators. Furthermore, the monoclonal antibodies AUA I,' Ca 2, and Ca 353 have been described as specific for malignant cells in serous effusions.
In our study the occurrence of cells positive for CEA, CA 19-9, or BGP I was specific for the presence of a carcinoma. Not all positive cells, however, seem to be carcinoma cells. Obviously, material derived from a tumour and phagocytosed by mesothelia had been stained in some cases. The morphology of the cells in immunocytochemically stained slides and the fact that positive cells were found mostly in effusions diagnosed as positive by conventional cytology, indicate that positively stained cells in most cases were carcinoma cells. Positively stained cells, however, were also found in 26% of serous effusions from patients with malignant disease which had been diagnosed cytologically as "negative" or "suspicious". Therefore, immunocytochemical staining for these antigens seems to be helpful in diagnosis, although even with anti-CEA, the most sensitive of the three antibodies, tumour cells could be detected in only 24% of carcinoma cases. Nevertheless, compared with conventional cytology alone, the additional use of immunocytochemistry raised the sensitivity of the detection of a carcinoma from 32% to 63%. In effusions selected for the presence of tumour cells, a staining of adenocarcin- Italy, 1984) and Bergmann et al67 seem to indicate that in some cases the production of the antigen in mesothelium might be the cause of raised serum concentrations.
High CA 125 concentrations in effusion fluid can also occur in benign disease and are therefore not a recommendation for the diagnostic use of this test. To obtain sufficient specificity our cut off value for TPA (2000 U/1) in serous effusion fluid had to be set much higher than the discriminatory limit recommended for serum TPA (80-120 U/1).6"' This resulted in comparatively low sensitivity and positive predictive values. For similar reasons, BGP I concentrations in pleural effusions seem to be less helpful in diagnosis.
In contrast, determination of CA 19-9 in ascitic and in pleural effusions and that of BGP I in ascitic effusions are specific and sensitive enough to become valuable tools in diagnosis, although these tests are similar to determination of CEA in serous effusion fluid and are positive in only about 1/3 to 1/2 of malignant cases. As the single antigens exhibited raised concentrations in different patient groups (depending partly on the site ofthe primary lesion), the combination of two or three markers increased the sensitivity considerably. For some combinations, however, the specificity was too low for clinical use.
In agreement with the reports of Martinez-Vea et al8 we found raised AFP concentrations in effusion 642 Mezger, Permanetter, Gerbes, Wilmanns, Lamerz fluid only rarely. This reflects the narrow range of tumours which usually express this antigen. Couch3 found that human ,B chorionic gonadotrophin gave a specificity for malignancy of 96% and a sensitivity of 36% at a cut offof 10 mIU/ml. High concentrations of a 1 -acidylglycoprotein in serous effusion fluid are not specific for malignancy, but in a series of 50 patients values below 39 ng/ml were found only in benign disease. 58 Until now tumour markers have not discriminated between benign and malignant aetiologies in serous effusions with satisfying sensitivity. On careful examination of benign specimens, however, cut off values can be derived for some antigens which are useful in identifying a tumour, especially an adenocarcinoma as the cause of the effusion. To date, the best antigen is CEA. As shown by our study, both the immunocytochemical staining for CA 19-9 and BGP I as well as the determination of the concentrations of these antigens in serous effusion fluid provide valuable additional information about the cause of pleural and peritoneal effusions. Depending on the circumstances, we recommend a combination of these methods to increase diagnostic accuracy. We thank Ms M Darsow, G Wochinger, A Brandt and E Segura for excellent technical assistance. Drs W Klaubert, KE Haiussinger, and F Cujnik generously provided effusion and serum specimens.
